Literature DB >> 25224185

Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis.

Kimiteru Ito1, Osamu Okazaki, Miyako Morooka, Kazuo Kubota, Ryogo Minamimoto, Michiaki Hiroe.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and assess the uptake pattern based on the free fatty acid (FFA) levels.
METHODS: Nineteen CS subjects who underwent (18)F-FDG PET/CT examinations with heparin loading (HL) were recruited to evaluate their CS activity. The (18)F-FDG uptake in the heart was classified into five categories ("none," "diffuse" and "diffuse at base," regarded as stable CS, and "focal" and "focal on diffuse," regarded as de novo or worsening CS). The subject data were compared with the (18)F-FDG PET/CT findings in 13 healthy volunteers. The FFA serum levels were assessed in 10 patients with CS and all volunteers.
RESULTS: The sensitivity and specificity of (18)F-FDG PET/CT with HL were 75% (6/8) and 73% (8/11), respectively. The major pattern of cardiac (18)F-FDG uptake was "diffuse at base." Ten of the 32 subjects, including the control group, exhibited this pattern. The FFA serum levels before heparin administration were statistically significantly different between the patients with the "none" pattern and those with the "diffuse" and "diffuse at base" patterns. There were no significant correlations between the FFA serum levels after heparin administration and the (18)F-FDG uptake patterns.
CONCLUSION: "Diffuse at base" is the major (18)F-FDG uptake pattern associated with inadequate physiologic (18)F-FDG suppression. This pattern should be carefully interpreted when examining the (18)F-FDG PET/CT images of CS patients. Additionally, increased FFAs levels associated with HL may not completely suppress the physiologic myocardial FDG uptake.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224185     DOI: 10.2169/internalmedicine.53.2491

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake.

Authors:  Osamu Manabe; Markus Kroenke; Tadao Aikawa; Atsuto Murayama; Masanao Naya; Atsuro Masuda; Noriko Oyama-Manabe; Kenji Hirata; Shiro Watanabe; Tohru Shiga; Chietsugu Katoh; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2017-12-14       Impact factor: 5.952

2.  Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Kenji Hirata; Souichiro Hayashi; Masanao Naya; Ichizo Tsujino; Tadao Aikawa; Kazuhiro Koyanagawa; Noriko Oyama-Manabe; Yuuki Tomiyama; Keiichi Magota; Keiichiro Yoshinaga; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

3.  FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation.

Authors:  Darshan C Patel; Senthil S Gunasekaran; Christopher Goettl; Nadera J Sweiss; Yang Lu
Journal:  J Nucl Cardiol       Date:  2017-07-05       Impact factor: 5.952

4.  Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Keunyoung Kim
Journal:  J Nucl Cardiol       Date:  2019-01-02       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.